P31 Interim analysis of EVOLVE: evaluating Eteplirsen, Golodirsen, or Casimersen treatment in patients < 7 years old in routine clinical practice

Current clinical recommendations for Duchenne muscular dystrophy (DMD) emphasize the importance of early diagnosis and treatment. Clinical trial 4658-102 (NCT03218995) demonstrated the safety and tolerability of eteplirsen in the youngest population of patients with DMD (6 to 48 months). Here, patients ’ (

Source: Neuromuscular Disorders - October 1, 2023 Category: Neurology Authors: S. Grabich, S. Santra, M. Waldrop, K. Mathews, F. Abid, L. Ramos-Platt, R. Scharf, C. Zaidman, I. Sehinovych, C. McDonald Source Type: research